Aaronson, N. K., Taphoorn, M. J., Heimans, J. J., Postma, T. J., Gundy, C. M., Beute, G. N., ... Klein, M. (2011). Compromised health-related quality of life in patients with low-grade glioma. Journal of Clinical Oncology, 29(33), 4430-5.

Albano, D., Tomasini, D., Bonù, M., Giubbini, R., & Bertagna, F. (2020). (18)F-Fluciclovine ((18)F-FACBC) PET/CT or PET/MRI in gliomas/glioblastomas. Annals of Nuclear Medicine, 34(2), 81-86.

Appelman-Dijkstra, N. M., Kokshoorn, N. E., Dekkers, O. M., Neelis, K. J., Biermasz, N. R., Romijn, J. A., ... Pereira, A. M. (2011). Pituitary dysfunction in adult patients after cranial radiotherapy: systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 96(8), 2330-40.

Armstrong, T. S., Grant, R., Gilbert, M. R., Lee, J. W., & Norden, A. D. (2016). Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy. Neuro-Oncology, 18(6), 779-89.

Bello, M. J., Alonso, M. E., Aminoso, C., Anselmo, N. P., Arjona, D., Gonzalez-Gomez, P., ... Rey, J. A. (2004). Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors. Mutation Research, 554(1-2), 23-32.

Berghoff, A. S., Stefanits, H., Woehrer, A., Heinzl, H., Preusser, M., & Hainfellner, J. A. (2013). Clinical neuropathology practice guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers. Clinical Neuropathology, 32(3), 148-58.

Bitar, R., Leung, G., Perng, R., Tadros, S., Moody, A. R., Sarrazin, J., ... Roberts, T. P. (2006). MR pulse sequences: what every radiologist wants to know but is afraid to ask. Radiographics, 26(2), 513-37.

Boele, F. W., Klein, M., Reijneveld, J. C., Verdonck-de Leeuw, I. M., & Heimans, J. J. (2014). Symptom management and quality of life in glioma patients. CNS oncology, 3(1), 37-47.

Borgen, T. T., Hjelle, A. M., Apalset, E. M., Hoff, M. (1. mai 2022). Osteoporose. I: Revmatologi (NRF) Nasjonal veileder. [nettdokument]. Oslo: Revmatologisk forening. Hentet fra https://metodebok.no/index.php?action=topic&item=AtEEtJ7q

Cairncross, G., Berkey, B., Shaw, E., Jenkins, R., Scheithauer, B., Brachman, D., ... Curran, W. (2006). Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology, 24(18), 2707-14.

Cairncross, G., Wang, M., Shaw, E., Jenkins, R., Brachman, D., Buckner, J., ... Mehta, M. (2013). Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of Clinical Oncology, 31(3), 337-43.

Capper, D., Reifenberger, G., French, P. J., Schweizer, L., Weller, M., Touat, M., ... van den Bent, M. J. (2023). EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. Neuro-Oncology, 25(5), 813-826.

Caroline, I., & Rosenthal, M. A. (2012). Imaging modalities in high-grade gliomas: pseudoprogression, recurrence, or necrosis?. Journal of Clinical Neuroscience, 19(5), 633-7.

Castillo, M. (2014). History and evolution of brain tumor imaging: insights through radiology. Radiology, 273(2 Suppl), S111-25.

Climans, S. A., Grunfeld, E., Mason, W. P., & Chan, K. K. W. (2022). Effectiveness and safety of pneumocystis pneumonia prophylaxis for patients receiving temozolomide chemoradiotherapy. Neuro-Oncology, 24(10), 1738-1748.

Climans, S. A., Mason, W. P., Grunfeld, E., & Chan, K. (2022). Clinical features of glioma patients who develop pneumocystis pneumonia with temozolomide chemoradiotherapy. Journal of Neuro-Oncology, 159(3), 665-674.

Cote, D. J., & Smith, T. R. (2016). Venous thromboembolism in brain tumor patients. Journal of Clinical Neuroscience, 25, 13-8.

Dale, E., & Waldeland, E. (2018). Protonterapi - en realitet i Norge fra 2023. Tidsskrift for den Norske legeforening, 138(13)

Diaz, M., & Jo, J. (2022). Venous Thrombotic Events and Anticoagulation in Brain Tumor Patients. Current Oncology Reports, 24(4), 493-500.

Dontala, S., Conelly, J., Biermann, M. (Under publisering 2024). Nukleærmedisinsk bildediagnostikk. I: Nevrologi og nevrokirurgi: fra barn til voksen. (8 utg.). Bergen: Fagbokforlaget.

Ellingson, B. M., Bendszus, M., Boxerman, J., Barboriak, D., Erickson, B. J., Smits, M., ... Gilbert, M. R. (2015). Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro-Oncology, 17(9), 1188-98.

Englot, D. J., Chang, E. F., & Vecht, C. J. (2016). Epilepsy and brain tumors. Handbook of Clinical Neurology, 134, 267-85.

Finch, E., & Copland, D. A. (2014). Language outcomes following neurosurgery for brain tumours: a systematic review. NeuroRehabilitation, 34(3), 499-514.

Finnes, T. E., Eriksen, E. F., Pretorius, M., Syversen, U., Aarsetøy, H., Bollerslev, J., Hewitt, S. (2022). Glukokortikoid-indusert osteoporose. I: Endokrinologi (NEF) Nasjonal veileder. Oslo: Endokrinologisk forening. Hentet fra https://metodebok.no/index.php?action=topic&item=idkvJizx

Fisher, R. S., Acevedo, C., Arzimanoglou, A., Bogacz, A., Cross, J. H., Elger, C. E., ... Wiebe, S. (2014). ILAE official report: a practical clinical definition of epilepsy. Epilepsia, 55(4), 475-82.

Gehring, K., Sitskoorn, M. M., Gundy, C. M., Sikkes, S. A., Klein, M., Postma, T. J., ... Aaronson, N. K. (2009). Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. Journal of Clinical Oncology, 27(22), 3712-22.

Gehring, K., Sitskoorn, M. M., Aaronson, N. K., & Taphoorn, M. J. (2008). Interventions for cognitive deficits in adults with brain tumours. Lancet Neurology, 7(6), 548-60.

Hegi, M. E., Diserens, A. C., Gorlia, T., Hamou, M. F., de Tribolet, N., Weller, M., ... Stupp, R. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. New England Journal of Medicine, 352(10), 997-1003.

Helse- og omsorgsdepartementet (2006). Nasjonal strategi for kreftområdet 2006-2009. Oslo: Helse- og omsorgsdepartementet. Hentet fra https://www.regjeringen.no/no/dokumenter/nasjonal-strategi-for-kreftomradet/id446845/

Helse- og omsorgsdepartementet (2006). Nasjonal helseplan (2007–2010). Oslo: Helse- og omsorgsdepartementet. Hentet Særtrykk av St.prp. nr. 1 (2006–2007) kapittel 6 fra https://www.regjeringen.no/globalassets/upload/hod/sykehus/nasjonal_helseplan_sartrykk.pdf

Helse- og omsorgsdepartementet (2013). Sammen - mot kreft: nasjonal kreftstrategi 2013-2017. Oslo: Helse- og omsorgsdepartementet. Hentet fra https://www.regjeringen.no/no/dokumenter/sammen---mot-kreft/id728818/

Helse- og omsorgsdepartementet (2018). Leve med kreft: nasjonal kreftstrategi (2018–2022). Oslo: Helse- og omsorgsdepartementet. Hentet fra https://www.regjeringen.no/no/dokumenter/leve-med-kreft/id2598282/

Helsedirektoratet (2022). Pneumocystis jirovecii-pneumoni, profylakse. I: Antibiotika i sykehus: nasjonal faglig retningslinje. Oslo: Helsedirektoratet. Hentet fra https://www.helsedirektoratet.no/retningslinjer/antibiotika-i-sykehus/soppinfeksjoner-invasive/pneumocystis-jirovecii-pneumoni-profylakse

Hemminki, K., Tretli, S., Olsen, J. H., Tryggvadottir, L., Pukkala, E., Sundquist, J., & Granstrom, C. (2010). Familial risks in nervous system tumours: joint Nordic study. British Journal of Cancer, 102(12), 1786-90.

Hemminki, K., Tretli, S., Sundquist, J., Johannesen, T. B., & Granstrom, C. (2009). Familial risks in nervous-system tumours: a histology-specific analysis from Sweden and Norway. Lancet Oncology, 10(5), 481-8.

Hodepine I: Legevakthåndboken (2021). (7 utg.). Oslo: Gyldendal. Hentet fra https://www.lvh.no/symptomer_og_sykdommer/nervesystemet/symptomdiagnoser/hodepine

Huang, M. E., Cifu, D. X., & Keyser-Marcus, L. (1998). Functional outcome after brain tumor and acute stroke: a comparative analysis. Archives of Physical Medicine and Rehabilitation, 79(11), 1386-90.

Huang, R. Y., Neagu, M. R., Reardon, D. A., & Wen, P. Y. (2015). Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response. Frontiers in Neurology, 6, 33.

Ichimura, K., Narita, Y., & Hawkins, C. E. (2015). Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers. Acta Neuropathologica, 129(6), 789-808.

Indelicato, D. J., Merchant, T., Laperriere, N., Lassen, Y., Vennarini, S., Wolden, S., ... Kortmann, R. D. (2016). Consensus Report From the Stockholm Pediatric Proton Therapy Conference. International Journal of Radiation Oncology, Biology, Physics, 96(2), 387-392.

Jordan, B., Margulies, A., Cardoso, F., Cavaletti, G., Haugnes, H. S., Jahn, P., ... Jordan, K. (2020). Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Annals of Oncology, 31(10), 1306-1319.

Karlberg, A., Berntsen, E. M., Johansen, H., Skjulsvik, A. J., Reinertsen, I., Dai, H. Y., ... Eikenes, L. (2019). 18F-FACBC PET/MRI in Diagnostic Assessment and Neurosurgery of Gliomas. Clinical Nuclear Medicine, 44(7), 550-559.

Kerkhof, M., & Vecht, C. J. (2013). Seizure characteristics and prognostic factors of gliomas. Epilepsia, 54 Suppl 9, 12-7.

Kerrigan, S., & Grant, R. (2011). Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database of Systematic Reviews, (8), CD008586.

Khan, F., Amatya, B., Ng, L., Drummond, K., & Galea, M. (2015). Multidisciplinary rehabilitation after primary brain tumour treatment. Cochrane Database of Systematic Reviews, (8), CD009509.

Khan, R. B., & Onar, A. (2006). Seizure recurrence and risk factors after antiepilepsy drug withdrawal in children with brain tumors. Epilepsia, 47(2), 375-9.

Khan, T., Akhtar, W., Wotton, C. J., Hart, Y., Turner, M. R., & Goldacre, M. J. (2011). Epilepsy and the subsequent risk of cerebral tumour: record linkage retrospective cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 82(9), 1041-5.

Koubeissi, M. (2014). Do we need seizure prophylaxis for brain tumor surgery?. Epilepsy Currents, 14(1), 24-5.

Kreftregisteret (2023). Årsrapport 2022: resultater og forbedringstiltak fra Kvalitetsregister for hjerne- og ryggmargssvulster. Oslo: Kreftregisteret. Hentet fra https://www.kreftregisteret.no/globalassets/publikasjoner-og-rapporter/arsrapporter/publisert-2023/arsrapport-2022-nasjonalt-kvalitetsregister-for-hjerne--og-ryggmargssvulster.pdf

Kyriakakis, N., Lynch, J., Orme, S. M., Gerrard, G., Hatfield, P., Short, S. C., ... Murray, R. D. (2019). Hypothalamic-pituitary axis irradiation dose thresholds for the development of hypopituitarism in adult-onset gliomas. Clinical Endocrinology, 91(1), 131-140.

Landberg, T., Chavaudra, J., Dobbs, J., Gerard, J. P., Hanks, G., Horiot, J. C., ... Svensson, H. (1999). Report 62: prescribing, recording and reporting photon beam therapy (Supplement to ICRU report 50). Journal of the International Commission on Radiation Units and Measurements, os32(1)

Landberg, T., Chavaudra, J., Dobbs, J., Hanks, G., Johansson, K., Möller, T., & Purdy, J. (1993). Report 50: Prescribing, Recording, and Reporting Photon Beam Therapy. Journal of the International Commission on Radiation Units and Measurements, os26(1)

Larsen, I. K. (2022). Cancer in Norway 2021 - cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway. Hentet fra https://www.kreftregisteret.no/globalassets/cancer-in-norway/2021/cin_report.pdf

Law, I., Albert, N. L., Arbizu, J., Boellaard, R., Drzezga, A., Galldiks, N., ... Weller, M. (2019). Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 46(3), 540-557.

Le Rhun, E., Guckenberger, M., Smits, M., Dummer, R., Bachelot, T., Sahm, F., ... Preusser, M. (2021). EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Annals of Oncology, 32(11), 1332-1347.

Lee, E. Q., Wen, P. Y. (24. april 2020). Treatment and prevention of venous thromboembolism in patients with brain tumors. [database]. Waltham, MA: UpToDate, Inc. Hentet 8. juni 2020 fra https://www.uptodate.com/contents/treatment-and-prevention-of-venous-thromboembolism-in-patients-with-brain-tumors

Leske, H., Dalgleish, R., Lazar, A. J., Reifenberger, G., & Cree, I. A. (2021). A common classification framework for histone sequence alterations in tumours: an expert consensus proposal. Journal of Pathology, 254(2), 109-120.

Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current knowledge and future directions. Neuro-Oncology, 11(3), 330-9.

Mabray, M. C., Barajas, R. F. ,. J., & Cha, S. (2015). Modern brain tumor imaging. Brain tumor research and treatment, 3(1), 8-23.

Majos, C., Aguilera, C., Alonso, J., Julia-Sape, M., Castaner, S., Sanchez, J. J., ... Arus, C. (2009). Proton MR spectroscopy improves discrimination between tumor and pseudotumoral lesion in solid brain masses. AJNR: American Journal of Neuroradiology, 30(3), 544-51.

Malmstrom, A., Gronberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., ... Henriksson, R. (2012). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncology, 13(9), 916-26.

Mehta, P., Fahlbusch, F. B., Rades, D., Schmid, S. M., Gebauer, J., & Janssen, S. (2019). Are hypothalamic- pituitary (HP) axis deficiencies after whole brain radiotherapy (WBRT) of relevance for adult cancer patients? - a systematic review of the literature. BMC Cancer, 19(1), 1213.

Michaud, D., Batchelor, T. (2017). Risk factors for brain tumors. [database]. Waltham, MA.: UpToDate, Inc.

Mikulis, D. J., & Roberts, T. P. (2007). Neuro MR: protocols. Journal of Magnetic Resonance Imaging, 26(4), 838-47.

Nayak, L., DeAngelis, L. M., Brandes, A. A., Peereboom, D. M., Galanis, E., Lin, N. U., ... Reardon, D. A. (2017). The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro-Oncology, 19(5), 625-635.

Nelson, S., & Taylor, L. P. (2014). Headaches in brain tumor patients: primary or secondary?. Headache, 54(4), 776-85.

O'Dell, M. W., Barr, K., Spanier, D., & Warnick, R. E. (1998). Functional outcome of inpatient rehabilitation in persons with brain tumors. Archives of Physical Medicine and Rehabilitation, 79(12), 1530-4.

Ostrom, Q. T., Cioffi, G., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2021). CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. Neuro-Oncology, 23(12 Suppl 2), iii1-iii105.

Ostrom, Q. T., Gittleman, H., Liao, P., Vecchione-Koval, T., Wolinsky, Y., Kruchko, C., & Barnholtz-Sloan, J. S. (2017). CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro-Oncology, 19(suppl_5), v1-v88.

Ostrom, Q. T., Patil, N., Cioffi, G., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2020). CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro-Oncology, 22(12 Suppl 2), iv1-iv96.

Ostrom, Q. T., Wright, C. H., & Barnholtz-Sloan, J. S. (2018). Brain metastases: epidemiology. Handbook of Clinical Neurology, 149, 27-42.

Pekmezci, M., & Perry, A. (2013). Neuropathology of brain metastases. Surgical Neurology International, 4(Suppl 4), S245-55.

Perry, J. R. (2010). Anticoagulation of malignant glioma patients in the era of novel antiangiogenic agents. Current Opinion in Neurology, 23(6), 592-6.

Perucca, E. (2013). Optimizing antiepileptic drug treatment in tumoral epilepsy. Epilepsia, 54 Suppl 9, 97-104.

Preusser, M., Berghoff, A. S., Manzl, C., Filipits, M., Weinhausel, A., Pulverer, W., ... Hainfellner, J. A. (2014). Clinical Neuropathology practice news 1-2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma. Clinical Neuropathology, 33(1), 6-14.

Quant, E. C., & Wen, P. Y. (2011). Response assessment in neuro-oncology. Current Oncology Reports, 13(1), 50-6.

Report 83: Prescribing, Recording, and Reporting Intensity-Modulated Photon-Beam Therapy (IMRT) (2010). Journal of the International Commission on Radiation Units and Measurements, 10(1)

Roberts, T. P., & Mikulis, D. (2007). Neuro MR: principles. Journal of Magnetic Resonance Imaging, 26(4), 823-37.

Rogers, L., Barani, I., Chamberlain, M., Kaley, T. J., McDermott, M., Raizer, J., ... Vogelbaum, M. A. (2015). Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. Journal of Neurosurgery, 122(1), 4-23.

Roth, P., Pace, A., Le Rhun, E., Weller, M., Ay, C., Cohen-Jonathan Moyal, E., ... Preusser, M. (2021). Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. Annals of Oncology, 32(2), 171-182.

Roth, P., Wick, W., & Weller, M. (2010). Steroids in neurooncology: actions, indications, side-effects. Current Opinion in Neurology, 23(6), 597-602.

Sanson, M., Marie, Y., Paris, S., Idbaih, A., Laffaire, J., Ducray, F., ... Delattre, J. Y. (2009). Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. Journal of Clinical Oncology, 27(25), 4150-4.

Schiff, D., Lee, E. Q., Nayak, L., Norden, A. D., Reardon, D. A., & Wen, P. Y. (2015). Medical management of brain tumors and the sequelae of treatment. Neuro-Oncology, 17(4), 488-504.

Shaw, E., Arusell, R., Scheithauer, B., O'Fallon, J., O'Neill, B., Dinapoli, R., ... Abrams, R. (2002). Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. Journal of Clinical Oncology, 20(9), 2267-76.

Silvani, A., Gaviani, P., Lamperti, E., Botturi, A., Ferrari, D., Simonetti, G., ... Salmaggi, A. (2011). Metabolic, electrolytes disorders and tromboembolic risk in malignant glioma patients. Neurological Sciences, 32 Suppl 2, S229-31.

Singh, R., Lehrer, E. J., Wang, M., Perlow, H. K., Zaorsky, N. G., Trifiletti, D. M., ... Palmer, J. D. (2021). Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials. International Journal of Radiation Oncology, Biology, Physics, 111(2), 371-384.

Soffietti, R., Baumert, B. G., Bello, L., von Deimling, A., Duffau, H., Frenay, M., ... Wick, W. (2010). Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. European Journal of Neurology, 17(9), 1124-33.

Stern, A., Green, H., Paul, M., Vidal, L., & Leibovici, L. (2014). Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database of Systematic Reviews, 2014(10), CD005590.

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., ... Mirimanoff, R. O. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine, 352(10), 987-96.

Stupp, R., Tonn, J. C., Brada, M., & Pentheroudakis, G. (2010). High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 21 Suppl 5, v190-3.

Svolos, P., Kousi, E., Kapsalaki, E., Theodorou, K., Fezoulidis, I., Kappas, C., & Tsougos, I. (2014). The role of diffusion and perfusion weighted imaging in the differential diagnosis of cerebral tumors: a review and future perspectives. Cancer Imaging, 14, 20.

Taillibert, S., Taillandier, L., & Le Rhun, E. (2015). Venous thrombosis in patients with high-grade glioma. Current Opinion in Neurology, 27(6), 516-21.

Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with brain tumours. Lancet Neurology, 3(3), 159-68.

Taplitz, R. A., Kennedy, E. B., Bow, E. J., Crews, J., Gleason, C., Hawley, D. K., ... Flowers, C. R. (2018). Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. Journal of Clinical Oncology, 36(30), 3043-3054.

Tran, D. K., & Jensen, R. L. (2013). Treatment-related brain tumor imaging changes: So-called "pseudoprogression" vs. tumor progression: Review and future research opportunities. Surgical Neurology International, 4(Suppl 3), S129-35.

Tremont-Lukats, I. W., Ratilal, B. O., Armstrong, T., & Gilbert, M. R. (2008). Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database of Systematic Reviews, (2), CD004424.

van Breemen, M. S., Wilms, E. B., & Vecht, C. J. (2007). Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurology, 6(5), 421-30.

van den Bent, M. J., Brandes, A. A., Taphoorn, M. J., Kros, J. M., Kouwenhoven, M. C., Delattre, J. Y., ... Hoang-Xuan, K. (2013). Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of Clinical Oncology, 31(3), 344-50.

van den Bent, M. J., Carpentier, A. F., Brandes, A. A., Sanson, M., Taphoorn, M. J., Bernsen, H. J., ... Gorlia, T. (2006). Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of Clinical Oncology, 24(18), 2715-22.

Verger, A., Kas, A., Darcourt, J., & Guedj, E. (2022). PET Imaging in Neuro-Oncology: An Update and Overview of a Rapidly Growing Area. Cancers, 14(5)

Waagemans, M. L., van Nieuwenhuizen, D., Dijkstra, M., Wumkes, M., Dirven, C. M., Leenstra, S., ... Stalpers, L. J. (2011). Long-term impact of cognitive deficits and epilepsy on quality of life in patients with low-grade meningiomas. Neurosurgery, 69(1), 72-8; discussion 78-9.

Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., ... Chang, S. M. (2010). Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. Journal of Clinical Oncology, 28(11), 1963-72.

WHO Classification of Tumours Editorial Board (2021). Central Nervous System Tumours. (5 utg.). Lyon: IARC Press.

WHO Classification of Tumours Editorial Board (2022). Endocrine and neuroendocrine tumours. (5 utg.). Lyon: IARC Press.

Wick, W., Meisner, C., Hentschel, B., Platten, M., Schilling, A., Wiestler, B., ... Weller, M. (2013). Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology, 81(17), 1515-22.

Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., ... Weller, M. (2012). Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncology, 13(7), 707-15.

Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., ... Bigner, D. D. (2009). IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine, 360(8), 765-73.

Zhang, J., Walsh, M. F., Wu, G., Edmonson, M. N., Gruber, T. A., Easton, J., ... Downing, J. R. (2015). Germline Mutations in Predisposition Genes in Pediatric Cancer. New England Journal of Medicine, 373(24), 2336-2346.

Zucchella, C., Capone, A., Codella, V., De Nunzio, A. M., Vecchione, C., Sandrini, G., ... Bartolo, M. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by primary brain tumor: a randomized, controlled trial. Journal of Neuro-Oncology, 114(1), 93-100.